Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 6/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | USP8 | P40818 | 1/20 | 0.37 |
| ▸ | USP7 | Q93009 | 1/20 | 0.37 |
| ▸ | USP47 | Q96K76 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2652165 | 0.84 | SQOR (0.39) | CYP11B2SQORCNR2SCN9AUSP8 | |
| SCHEMBL3291131 | 0.81 | ADORA1 (0.46) | CYP11B2SQORGABRG2GABRB3GABRA5 | |
| SCHEMBL19072688 | 0.80 | MAPK14 (0.48) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL3288797 | 0.78 | GABRG2 (0.47) | CYP11B2SQORGABRG2GABRB3GABRA5 | |
| SCHEMBL26185770 | 0.76 | ADORA2A (0.46) | CYP11B2GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL30709648 | 0.76 | ADORA2A (0.46) | CYP11B2GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2654322 | 0.76 | CYP11B2 (0.39) | CYP11B2GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL21116203 | 0.75 | USP8 (0.42) | CYP11B2GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2651557 | 0.75 | BCAT1 (0.37) | CYP11B2GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL3863531 | 0.75 | CYP11B1 (0.44) | CYP11B2GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226926-B2 | 8-fluoroimidazo 1,2-a pyridine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. (GB) | 2007-06-05 | — | — | US | disclosed |
| EP-1511748-B1 | 8-FLUORIMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2006-08-09 | — | — | EP | disclosed |
| US-20060052385-A1 | 8-Fluoroimidazo 1,2-a pyridine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2006-03-09 | — | — | US | disclosed |
| EP-1511748-A1 | 8-FLUORIMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003099817-A1 | 8-FLUORIMIDAZO`1,2-A!PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052385-A1 | 8-Fluoroimidazo 1,2-a pyridine derivatives as ligands for gaba receptors | GABRA3, GABRA2, GABRA5 | CYP11B2 567/4885SQOR 3158/4885GABRG2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.